FDA Restructure: New Deputy Roles for Tech and Drugs Under HHS Plan

The U.S. Department of Health and Human Services (HHS) is reportedly planning to restructure the Food and Drug Administration's (FDA) leadership by adding two new deputy commissioner positions—one dedicated to technology and artificial intelligence, and another focused on drugs. This move comes at a critical juncture as the FDA grapples with high-profile drug approvals, food safety scandals, and the rapid integration of AI into healthcare. Sources familiar with the plan indicate that these roles are part of a broader effort by the Trump administration to exert greater influence over the agency. With the FDA facing intense scrutiny over its handling of foodborne outbreaks and controversial drug decisions, this leadership overhaul could signal a new era of regulatory priorities.

Key Details

• New Deputy Commissioner for Technology: This role would oversee both the FDA's internal use of AI (like the Elsa generative AI tool) and its review of AI-enabled medical devices. Jared Seehafer, a former CEO of Enzyme and current senior advisor to the FDA, is the leading candidate.
• New Deputy Commissioner for Drugs: This position would focus on drug regulation, though no specific candidates have been identified yet. The role comes amid a series of contentious drug approvals and rejections.
• Reporting Structure: Both new deputy commissioners would report directly to Heidi Overton, President Trump's nominee for FDA commissioner, pending Senate confirmation.
• Leadership Context: The FDA has been without a permanent commissioner since Marty Makary's resignation in May over the agency's authorization of fruit-flavored vapes. Kyle Diamantas, the current acting commissioner, previously served as deputy commissioner for food.
• Recent FDA Controversies: The agency faced backlash for its initial rejection of Replimune's melanoma drug (later granted accelerated approval) and for demanding a sham brain surgery trial for UniQure's Huntington's disease treatment (later reversed).
• AI in Healthcare: The FDA has increasingly used AI internally and released a discussion paper on regulating generative AI-enabled medical devices, seeking stakeholder input.
• Food Safety Concerns: The FDA's handling of a cyclospora outbreak linked to iceberg lettuce has raised questions about budget cuts and staffing shortages affecting its ability to protect public health.

In-Depth Analysis

The proposed restructuring of the FDA's leadership reflects a strategic response to the converging challenges of technological innovation and regulatory accountability. The creation of a deputy commissioner for technology underscores the agency's recognition that AI is no longer a peripheral tool but a central force in both drug development and medical device functionality. By appointing a dedicated leader for this domain, the FDA aims to streamline its oversight of AI-enabled products, which have proliferated in recent years. This move is particularly timely given the agency's recent discussion paper on generative AI devices—a signal that formal guidance may be on the horizon.

However, the political undertones of this restructuring cannot be ignored. By placing loyalists in key deputy roles, the Trump administration may be seeking to align the FDA's regulatory philosophy with its broader agenda of deregulation and faster drug approvals. This could lead to tensions with public health advocates who worry about the erosion of safety standards. The drug deputy role, for instance, will inherit a portfolio marked by high-stakes decisions, such as the controversial approval of Replimune's melanoma therapy and the backlash over UniQure's trial demands. Balancing innovation with patient safety will be a delicate act.

Looking ahead, the success of these new roles will depend on the Senate's confirmation of Heidi Overton and the ability of the new deputies to navigate the agency's complex internal dynamics. The tech deputy, if filled by Seehafer, would bring industry experience but may face skepticism from career scientists. Meanwhile, the FDA's ongoing struggles with foodborne outbreaks highlight systemic issues that no single leadership change can fix. Ultimately, this restructuring is a test of whether the FDA can modernize its operations without compromising its core mission.

Frequently Asked Questions

What will the new deputy commissioner for technology do? This role will oversee the FDA's internal use of AI, such as the Elsa tool for document summarization, and will also lead the agency's review of AI-enabled medical devices. The goal is to ensure that the FDA keeps pace with technological advancements while maintaining safety standards.

Why is the FDA creating a deputy commissioner for drugs when it already has drug centers? The new role is designed to provide high-level strategic oversight of drug regulation, particularly in light of recent controversies over drug approvals and rejections. It would coordinate across the agency's drug centers and serve as a single point of accountability for drug-related decisions.

Will these changes affect the FDA's food safety oversight? While the new roles focus on technology and drugs, the FDA's food safety responsibilities remain unchanged. However, the agency's handling of recent outbreaks may be influenced by broader leadership shifts and resource allocation decisions.

Source: https://www.cnbc.com/2026/08/25/hhs-fda-leadership-roles-technology-drugs.html